CSIMarket Company Name, Ticker, Industry, else..
 
Lineage Cell Therapeutics Inc   (NYSE: LCTX)
 
Price: $1.0800 $-0.02 -1.818%
Day's High: $1.1100000143051147 Week Perf: -1.82 %
Day's Low: $ 1.08 30 Day Perf: -4.42 %
Volume (M): 535,700 52 Wk High: $ 2.09
Volume (M$): $ 0 52 Wk Avg: $1.51
Open: $1.09 52 Wk Low: $1.00



 Market Capitalization (Millions $) 282
 Shares Outstanding (Millions) 261
 Employees 77
 Revenues (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -64
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 0

Business Description


Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company that focuses on developing and commercializing novel cell therapies for the treatment of degenerative diseases. The company's technology platform involves the use of pluripotent stem cells to create cell-based therapies to restore or replace damaged cells in the body. Lineage Cell Therapeutics is primarily focused on developing treatments for conditions such as age-related macular degeneration, spinal cord injuries, and osteoarthritis. The company's goal is to improve the quality of life for patients by providing innovative and effective treatment options.


   Company Address: 2173 Salk Avenue Carlsbad 92008 CA
   Company Phone Number: 287-8990   Stock Exchange / Ticker: NYSE LCTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BPSR   -1.64%    
HUMA   -6.92%    
SNTI   -11.67%    
TIL      0% 
VCEL   -1.86%    
VIVS   -3.45%    
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 19.09
Price to Sales (Expected) -
Price to Book 5.35
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.55
Working Capital Ratio 6.89
Leverage Ratio (MRQ) 1.06
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.29 $
Revenues (TTM) 0.06 $
Cash Flow (TTM) -
Cash 0.2 $
Book Value 0.2 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 191,935
Net Income per Employee (TTM) -831,338
Receivable Turnover Ratio (TTM) 28.42
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.15

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -440.17 %
Net Margin (MRQ) -277.62 %
Net Cash Flow Margin (MRQ) -281.04 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Lineage Cell Therapeutics Inc's Segments
Upfront License Fees    49.86 % of total Revenue
Event Based Milestones and Other Collaborative Revenue    6.55 % of total Revenue
Royalties License and Other Revenues    1.28 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.